Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.

ABSTRACT:

Background

Opioid agonist therapy is strongly recommended for pregnant persons with opioid use disorder. Buprenorphine may be associated with more favorable neonatal and maternal outcomes than methadone, but existing data are limited.

Methods

We conducted a cohort study involving pregnant persons who were enrolled in public insurance programs in the United States during the period from 2000 through 2018 in which we examined outcomes among those who received buprenorphine as compared with those who received methadone. Exposure to the two medications was assessed in early pregnancy (through gestational week 19), late pregnancy (gestational week 20 through the day before delivery), and the 30 days before delivery. Risk ratios for neonatal and maternal outcomes were adjusted for

SUBMITTER: Suarez EA 

PROVIDER: S-EPMC9873239 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature